Working… Menu

Local Intraoperative Analgesic Injection Versus Single Injection Interscalene Nerve Block in Patients Undergoing TSA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02695758
Recruitment Status : Completed
First Posted : March 1, 2016
Last Update Posted : March 1, 2016
Information provided by (Responsible Party):
Rothman Institute Orthopaedics

Brief Summary:
A non-blinded randomized controlled trial, in which participants undergoing primary reverse or total shoulder arthroplasty are randomly assigned to one of two treatment groups.

Condition or disease Intervention/treatment Phase
Osteoarthritis: Shoulder Procedure: Interscalene brachial plexus block Procedure: bupivacaine extended-release liposome injection Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 156 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Local Intraoperative Analgesic Injection Versus Single Injection Interscalene Nerve Block in Patients Undergoing Shoulder Arthroplasty (TSA): A Randomized Trial
Study Start Date : December 2014
Actual Primary Completion Date : December 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: interscalene brachial plexus block
Direct interscalene nerve block injection via brachial plexus
Procedure: Interscalene brachial plexus block
Active Comparator: Bupivacaine extended-release liposome injection
Infiltration of local anesthetic/analgesic, Bupivacaine extended-release liposome injection (Exparel) + Diluted in 40cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues.
Procedure: bupivacaine extended-release liposome injection

Primary Outcome Measures :
  1. Morphine and Morphine Equivalent consumption [ Time Frame: 24 hours following surgery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. All individuals undergoing primary reverse and total shoulder arthroplasty by the shoulder service at Methodist Hospital or Rothman Specialty Hospital.

Exclusion Criteria:

  1. Psychiatric illness as defined by co-morbid diagnosis of bipolar disorder or schizophrenia
  2. Revision arthroplasty, arthroplasty for fracture
  3. Unable/unwilling to consent for enrollment
  4. Unable to complete postoperative pain survey
  5. Known adverse drug reaction or allergy to the medications used
  6. Chronic pain syndromes (including reflex sympathetic dystrophy, fibromyalgia, chronic diffuse musculoskeletal pain)
  7. Patients taking long acting narcotic pain medications (including extended release narcotic pain medications and methadone).
  8. Patients under the age of 18 years
  9. Patients with history of hepatic disease
  10. Pregnant women or women who are breastfeeding
Layout table for additonal information
Responsible Party: Rothman Institute Orthopaedics Identifier: NCT02695758    
Other Study ID Numbers: 2016Nam2
First Posted: March 1, 2016    Key Record Dates
Last Update Posted: March 1, 2016
Last Verified: February 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents